Furthermore, a CAR construct-specific for both Her2 and Muc1 had promising in vitro results in a breast cancer model [120] and a dual-target CAR-T cells targeting Her2 and IL13Ra2 showed greater success than single-target CAR-T cells in a xenograft glioma model [121]. This evidence concerns the gene ERBB2 and central nervous system cancer.